Table 4.

Follow-up protocol after completion of radioligand therapy recommended in the NANETS/SNMMI guidelines [21]

Time after treatmenta	Clinical evaluation	Laboratory testsb	Tumour markersc	Diagnostic imaging
2–4 weeks	✓	✓		✓d
2 months		✓
3 months	✓	✓	Per team
6 months	✓	✓	Per team	✓
12 months	✓	✓	Per team	✓
Long term	Per team	Per team	Per team	Per team

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, NANETS North American neuroendocrine tumor society, RLT radioligand therapy, SNMMI society of nuclear medicine and molecular imaging

^aIncrease monitoring as needed based on patient’s clinical presentation, symptoms, concern about progressive disease, or post-treatment sequelae

^bComplete blood count with differential, ALP, ALT, AST, total bilirubin, and serum creatinine/GFR

^cMonitoring of markers should be based on clinical indication/presentation

^dImaging is recommended once between 1 and 3 months after RLT